Noninvasive Continuous Measurement of SpHb After Spontaneous Vaginal Delivery
NCT ID: NCT01505192
Last Updated: 2012-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2011-12-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
During labor all parturients will be tested for standard Laboratory Hb and monitored for at least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the baseline values.
Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb determination and Radical 7 equipment for SpHb will be connected to the patient's finger and will be recorded for at least two hours after delivery. At the end of this period of observation a venous blood sample will be taken for Hb determination. Additional measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-Invasive Measurement of Hemoglobin (Using Pulse Co-Oximetry) in Patients Undergoing Elective Cesarean Delivery
NCT01108471
Two Previous Cesarean and Vaginal Birth Before and After Starting Training and Protocols
NCT07258459
Non-invasive Hemoglobin Monitoring in Cesarean Section
NCT03409822
Continuous Non-Invasive Measurement of Hemoglobin During Parturition
NCT03150043
Uterine Rupture During Labor Among Women With a Prior Cesarean Delivery
NCT04566705
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pregnancy and childbirth involve health risks, even for women without any pre-existing health problems. Postpartum hemorrhage is one of most common complications for delivering mothers and causes 19% of in-hospital maternal deaths (Bateman BT et al. "The Epidemiology of Postpartum Hemorrhage in a Large, Nationwide Sample of Deliveries" Anesthesia and Analgesia 2010 110:1368-1373) . Due to pregnancy physiological changes, maternal bleeding is typically discovered after a significant change in vital signs, and/or symptoms, and usually confirmed with an invasive laboratory hemoglobin test. This can result in late detection of bleeding that can affect patient outcome. Early detection of signs and symptoms of obstetric hemorrhage is therefore crucial. Non-invasive and continuous hemoglobin (SpHb) monitoring system quickly measures current hemoglobin levels and continuously tracks them in real-time to detect falling hemoglobin levels that may, in turn, represent an early sign of a potential hemorrhage. Unfortunately there is no validation of the clinical accuracy of the Rainbow device for the noninvasive and continuous hemoglobin (SpHb) monitoring in the obstetric setting nor any information concerning its use as a tool for the early detection of postpartum hemorrhage.
The investigators therefore propose to undertake an open, preliminary, sequential pilot study to determine the physiological values (RI) of maternal continuous SpHb in the post-partum period.
Study Objective:
To determine the physiological reference individual values (RI) of maternal continuous SpHb immediately after delivery in the post-partum period (continuous monitoring up to 2 hours after delivery) in order to establish the physiological Hb variations in response to the physiological blood loss due to delivery.
Inclusion and exclusion criteria
Healthy parturients in labor will be asked to be enrolled in the study and informed consent will be obtained.Parturients will be consecutively included in this study. Bleeding risk subjects will be excluded (parturients who had:
Operative or instrumental vaginal delivery,Estimated blood loss greater than 500 mL, who had II and III degree perineal lacerations, any coagulation disorder or anticoagulant therapy)
Sample Size Since we have no available information on the expected distribution of the outcome, we will use a sequential design. The main endpoint of our analysis will be a reliable estimate for the outcome expected in healthy women after labor.
The investigators will state their target estimate as being reliable when the ratio between the estimate and its standard error is smaller than 2.
The International Federation of Clinical Chemistry (IFCC) and Clinical Laboratory and Standards Institute (CLSI) guidelines in 2008 recommended to establish RIs with at least 120 reference individuals using the nonparametric ranking method (Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Wayne, PA: CLSI; 2008) and thus we will include in the study a sample of at least 120.
Methods During labor all parturients will be tested for standard Laboratory Hb and monitored for at least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the baseline values.
Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb determination and Radical 7 equipment for SpHb will be connected to the patient's finger and will be recorded for at least two hours after delivery. At the end of this period of observation a venous blood sample will be taken for Hb determination. Additional measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.
According to the SpHB data collection-research protocol, sensor site will be connected to the patient's ring finger of the non-dominant hand. Sensor handling and placement will also follow the instructions of the SpHB data collection-research protocol.
Sensor will be attached to the same arm as the blood draw. Sensor placement on the hand of the side with the blood pressure cuff will be avoided unless they are drawing blood from that extremity. Placing the sensor and drawing blood from the same arm that is being used for IV infusions will be also avoided.
SpHb results will be not included when the Perfusion Index (PI, noninvasive index of peripheral perfusion and vasomotor tone) values will be less than 0.5.
Concerning blood sampling, blood will be drawn directly into the vacutainer by using a needle no smaller than 20G and analyzed within 15 min of the blood draw.
In Vivo adjustment and Trend Accuracy
SpHb accuracy with an in vivo adjustment will be calculated by using the new Radical 7 equipment with in vivo adjustment feature software which will take the bias between the first SpHb and first laboratory tHb measurement and will adjust all subsequent measurements for that case.
The trend accuracy will be calculated by using the following time points: pre-delivery, 2 hrs after delivery and 24 hr after delivery.
Calibrated SpHb measurements will be compared to subsequent laboratory values to create a Bland Altman plot and calculate bias, and confidence interval.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
continuous Hb monitor
Pre and post partum non invasive continuous Hb monitor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Città di Roma Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Silvia Stirparo
Staff Anesthesiologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silvia Stirparo, MD
Role: PRINCIPAL_INVESTIGATOR
Città di Roma Hospital
Giorgio Capogna, MD
Role: STUDY_CHAIR
Cittàdi Roma Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Città di Roma Hospital
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Postpartum non invasive Hb
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.